U. Bakay and T. İzci Duran, “Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a Single-Center Cohort”, Archives of Rheumatology, vol. 40, no. 4, pp. 465–473, Dec. 2025.